Optimi Health (OPTI) AI Stock Analysis

• Market Cap: C$28.99M
• Dividend Yield: N/A
• Average Volume (3M): 169.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: 65.16%
• EPS Growth: 33.18%
• Country: CA
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Agricultural Farm Products
• EPS (TTM): >-0.01
• Shares Outstanding: 96,638,170
• 10 Day Avg. Volume: 137,724
• 30 Day Avg. Volume: 169,715
• PEG Ratio: -0.28
• Price to Book (P/B): 2.24
• Price to Sales (P/S): 55.12
• P/FCF Ratio: -4.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: C$0.50 ▲(56.25% Upside)

Optimi Health's overall score is primarily impacted by its financial performance, which shows potential but is hindered by persistent losses and cash flow challenges. Technical analysis provides some positive momentum signals, but valuation concerns due to negative earnings weigh heavily on the score.

Optimi Health Business Overview & Revenue Model

Company Description

Optimi Health (OPTI) is a health and wellness company focused on providing innovative solutions in the realm of mental health and well-being. Operating primarily within the digital health sector, Optimi Health offers a range of products and services, including telehealth consultations, online therapy platforms, and digital wellness programs designed to improve mental health and overall quality of life. The company aims to leverage technology to make mental health support more accessible and effective for individuals and organizations.

How the Company Makes Money

Optimi Health generates revenue through multiple channels including subscription fees for its telehealth and online therapy services, which provide users with access to licensed mental health professionals. Additionally, the company may earn income from partnerships with employers and organizations that integrate its wellness programs into their employee health initiatives. The revenue model is further supported by potential licensing agreements for its proprietary digital health technologies and platforms. Strategic collaborations with healthcare providers and insurers can also contribute to revenue growth by expanding the reach of its services and enhancing its offerings.

Optimi Health Financial Statement Overview

Summary

Optimi Health shows revenue growth and strong equity levels, suggesting potential for future profitability. However, persistent losses, negative cash flows, and reliance on external funding highlight significant financial risks. Improvement in operational efficiency and cash management is crucial.

Income Statement

Optimi Health's revenue has shown growth from $0 in 2020 to $389,850 in 2024, indicating an upward trend. However, the company has consistently reported negative net income, with a significant net loss of $6,035,859 in 2024. The gross profit margin for 2024 is relatively healthy at 69.5%, but the absence of EBIT and negative EBITDA highlight challenges in operational efficiency.

Balance Sheet

The company maintains a high equity ratio, with stockholders’ equity consistently exceeding total liabilities, indicating financial stability. The debt-to-equity ratio is moderate at 0.29 in 2024, suggesting manageable leverage. However, the declining trend in total assets and stockholders' equity since 2021 should be monitored.

Cash Flow

Optimi Health's cash flow demonstrates a challenging picture with negative operating and free cash flows in all observed years, reflecting cash management issues. The operating cash flow to net income ratio is negative, underscoring cash flow inadequacy to cover net losses. Despite positive financing cash flows, reliance on external financing is evident.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	490.33K	389.85K	181.09K	80.72K	0.00	0.00
Gross Profit	396.10K	270.91K	-157.04K	53.92K	-47.12K	-5.42K
EBITDA	-1.35M	-4.74M	-4.42M	-7.03M	-5.95M	-161.14K
Net Income	-2.36M	-6.04M	-5.19M	-7.38M	-6.04M	-169.22K
Balance Sheet
Total Assets	14.14M	14.55M	16.49M	16.82M	23.46M	6.17M
Cash, Cash Equivalents and Short-Term Investments	88.53K	103.66K	1.34M	1.89M	12.43M	4.47M
Total Debt	2.86M	2.75M	1.71M	157.58K	250.84K	156.32K
Total Liabilities	6.38M	4.98M	3.28M	797.66K	2.40M	882.66K
Stockholders Equity	7.75M	9.58M	13.21M	16.02M	21.07M	5.29M
Cash Flow
Free Cash Flow	-1.27M	-4.43M	-4.41M	-11.73M	-10.96M	-898.27K
Operating Cash Flow	-1.25M	-4.28M	-3.60M	-4.58M	-6.02M	-143.45K
Investing Cash Flow	-15.55K	-154.02K	-706.02K	-3.15M	-9.19M	-754.83K
Financing Cash Flow	1.25M	3.19M	3.76M	1.19M	19.18M	5.37M

Optimi Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Neutral. The current price of 0.32 is below the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.32, and above the 200-day MA of 0.22, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.81 is Neutral, neither overbought nor oversold. The STOCH value of 63.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:OPTI.

Optimi Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NLH	61 Neutral	C$26.19M	157.89	0.69%	―	19.61%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OPTI	51 Neutral	C$28.99M	-6.99	-44.37%	―	65.16%	33.18%
ROMJ	51 Neutral	$33.25M	183.33	0.61%	―	34.19%	―
CWEB	49 Neutral	$29.44M	-0.97	-85.33%	―	-5.03%	50.71%
PHRM	44 Neutral	C$11.83M	―	-112.32%	―	―	27.35%

Optimi Health Corporate Events

Optimi Health Achieves GMP Compliance and Enhances Market Liquidity

Optimi Health Corp. has successfully passed its Drug Establishment Licence inspection by Health Canada, achieving a GMP-compliant rating for the fabrication and distribution of pharmaceutical-grade psychedelic products. This certification allows Optimi to manufacture, label, package, distribute, and wholesale pharmaceutical psychedelics, including MDMA and psilocybin capsules for treating PTSD and TRD, which are currently prescribed in Australia. Additionally, Optimi has entered into a market-making service agreement with Independent Trading Group to enhance the liquidity of its shares on the Canadian Securities Exchange, aiming to maintain an orderly market.

Optimi Health’s Psilocybin Capsules Join Medibank’s Expanded Mental Health Program

Optimi Health’s 5mg psilocybin capsules have been selected for inclusion in Medibank’s psychotherapy program, which has expanded to cover Treatment-Resistant Depression. This inclusion marks a significant step for Optimi as it integrates its products into insurance-backed regulated care, highlighting the growing acceptance of psychedelic medicines in mental health treatment. Medibank’s initiative is part of a broader AUD $50 million commitment to enhance mental health access and innovation, reinforcing the strategic shift towards novel therapies like psilocybin and MDMA.

Optimi Health Corp. Announces U.S. IPO Filing

Optimi Health Corp., a Canadian manufacturer of MDMA and naturally-derived psilocybin, has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common shares in the United States. The company aims to list its shares on the Nasdaq Capital Market under the symbol ‘OPTH,’ with Titan Partners Group acting as the sole book-running manager for the offering. The completion of the offering is subject to market conditions and the SEC’s review process, with no assurance of its completion or the terms of the offering.

Optimi Health Expands Psychedelic Offerings in Australia with Psilocybin Launch

Optimi Health Corp. has launched its natural psilocybin capsules in Australia for the treatment of Treatment-Resistant Depression under the Authorised Prescriber Scheme. This follows the company’s successful introduction of MDMA sales for PTSD in Australia in 2024. The initial shipment of 1,000 capsules was manufactured at Optimi’s GMP-licensed facility in Canada and distributed through Mind Medicine Australia. This launch marks a significant milestone for Optimi, as both its psilocybin and MDMA products are now available through a regulated government program, enhancing its position in the psychedelic medicine market.

Optimi Health Enhances Investor Relations and Achieves Production Milestone

Optimi Health Corp. has entered into an agreement with MZ Investor Relations to enhance its capital markets strategy and investor engagement. Additionally, Optimi has achieved a production milestone by completing the manufacturing of over 3,000 GMP doses of psilocybin extract capsules, which will be used in treating Treatment-Resistant Depression and upcoming clinical trials.